文档介绍：吉非替尼二线治疗进展后联合培美曲塞治疗36例肺腺癌疗效
观察
吉非替尼二线治疗进展后联合培美曲塞治疗36例肺腺癌疗效观察
【摘要】目的：观察吉非替尼联合培美曲塞治疗吉非替尼二线治疗进展后肺腺癌的疗效 以及安全性。方法：选取我科2010年10月至2012年12月74例一线化疗进展后给予吉 非替尼治疗有效再次进展患者，随机分为治疗组和对照组两组，治疗组(36例)：培美曲 塞，静脉滴注500mg/m2；吉非替尼，口服250mg/日，21天为一周期；对照组(38例)： 单用培美曲塞500mg/m2,静脉滴注，21天为一周期。所有患者至少应用2个周期。结 果：观察组近期治疗效果优于对照组；与对照组相比，治疗组中位进展时间和中位生存期 均更长；两组不良反应无明显差异。结论：采用吉非替尼二线治疗进展后联合培美曲塞治 疗非小细胞癌肺腺癌，其治疗效果明显，毒副作用少，有利于提高肺腺癌患者的生活质 量，有望成为治疗NSCLC患者的一线治疗药物。
【关键词】吉非替尼；培美曲塞；肺腺癌Clinical observation of treatment combined with pemetrexed after gefitinib second-line therapy advanced on 36 patients with lung adenocarcinoma
[Abstract] Objective: To observe the clinical efficacy and safety of treatment combined with pemetrexed after gefitinib second-line therapy advanced on lung adenocarcinoma. Methods: Selecting 74 cases who were given gefitinib effective and then advanced after first-line chemotherapy advanced from October 2010 to
December 2012 in our department. Randomly divided into two groups, observation group (36 cases): Given pemetrexed, in intravenous drip, 500 mg/m2; gefitinib, in oral, 250 mg/day, 21 days for a cycle; control group (38 cases): given pemetrexed only, 500 mg/m2, in intravenous drip, 21 days for a cycle.
All patients were treated at least 2 cycles. Results:The clinical effects of observation group are superior to
control group; Compared with control group, the middle of followed-up time and the m